Berotralstat
Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema[1][2].
Product Specifications
CAS Number
1809010-50-1
Product Name Alternative
BCX7353
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Kallikrein
Type
Reference compound
Related Pathways
Immunology/Inflammation
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/berotralstat.html
Purity
99.70
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C(F)(F)F)=NN1C2=CC(CN)=CC=C2)NC3=CC([C@@H](C4=CC(C#N)=CC=C4)NCC5CC5)=CC=C3F
Molecular Formula
C30H26F4N6O
Molecular Weight
562.56
Precautions
H315, H319, H320
References & Citations
[1]Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020; S0091-6749 (20) 31484-6.|[2]Richard E. Kast, et al. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma. Neuroglia. 2024, 5 (3), 223-233.|[3]Perego F, et al., Current and emerging biologics for the treatment of hereditary angioedema. Expert Opin Biol Ther. 2019 Jun;19 (6) :517-526.|[4]Wan J, et al., Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood. Blood Adv. 2024 Jun 25;8 (12) :3045-3057.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
